Early cancer diagnostics - more precise detection and targeted therapies
Our interdisciplinary team of experts in biology, biotechnology, bioinformatics and medicine is also centrally involved in the three main programs of the KiTZ. We combine preclinical, translational and clinical research to improve the diagnostic accuracy and targeted treatment of tumors and sarcomas of the central nervous system.
A particular focus is on the early detection of cancer, especially through innovative molecular tumor analyses from liquid biopsies (body fluids such as blood or cerebrospinal fluid). We rely on close interdisciplinary collaboration with other KiTZ groups and international partners in order to quickly transfer new technologies into clinical practice.
Through our "bedside-to-bench" approach (reverse translation), we develop precise tumor models and test state-of-the-art diagnostic procedures. Our group is also involved in the INFORM (for recurrent malignancies) and MSP2.0 (molecular sarcoma pathology) platform programs, which enable rapid validation and clinical application of new methods.
Our goal: to detect cancer earlier, understand it better and treat it in a targeted manner - for improved treatment of affected children.
